Evaluating Rapamycin Treatment in Alzheimer's Disease Using Positron Emission Tomography

1. Clinical diagnosis of mild cognitive impairment (MCI), or dementia of Alzheimer's type

2. Amyloid positivity established with either amyloid positron emission tomography or cerebrospinal fluid analysis.

3. For subjects with dementia, the disease should be in an early stage, operationalized as:

4. Capable of giving, and has the capacity to give informed consent

5. Availability of a responsible study partner who can accompany the subject to all planned visits

6. Male or female between 50 and 80 years

7. Normal or clinically acceptable medical history, physical examination, and vital signs

1. History of any major disease that may interfere with safe engagement in the intervention (especially severe liver or kidney disease, or uncontrolled diabetes).

2. Central nervous system infarct, infection, or focal lesions of clinical significance on MRI scans.

3. Fulfills any contraindication for the use of sirolimus as per the summary of product characteristics, including but not restricted to:

4. Significant obesity

5. Untreated and clinically significant hyperlipidemia

6. Treatment with immunosuppressive medications within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted), or chemotherapeutic agents for malignancy within the last 3 years

7. Major surgery within 3 months prior to the planned start of sirolimus treatment, OR has major surgery planned during the period of the trial.

8. Use of experimental medications for Alzheimer's or any other investigational medication or device within 60 days. Participants who have been involved in a monoclonal antibody study are excluded unless it is known that they were receiving placebo in that trial